BioLineRx Expands GLIX1 Oncology Pipeline Amid Financial Restructuring

The company’s Phase 1/2a study for GLIX1 is currently in its second cohort, with the third expected to begin in September. Recent preclinical results have bolstered the case for the drug, showing potent antitumor activity in temozolomide-resistant models. Beyond glioblastoma, BioLineRx observed a strong synergistic effect between GLIX1 and PARP inhibitors in ovarian cancer, prompting plans to integrate an ovarian cancer arm into the ongoing Phase 2a expansion.

Financial pressure remains a primary focus, with the company’s cash balance standing at $13.1 million as of June 30. To extend its operational runway into the first half of 2027, the firm finalized an agreement for a $3.75 million stock offering. Research and development spending climbed to $2.9 million this quarter, driven by the GLIX1 project, while commercial sales of its approved product, APHEXDA, contributed $0.3 million in royalty revenue. Management is scheduled to review these developments and the trial trajectory in a conference call today.